nodes	percent_of_prediction	percent_of_DWPC	metapath
Regorafenib—DDR2—skin epidermis—vulva cancer	0.091	0.091	CbGeAlD
Regorafenib—FGFR2—skin epidermis—vulva cancer	0.0465	0.0465	CbGeAlD
Regorafenib—KIT—skin epidermis—vulva cancer	0.0323	0.0323	CbGeAlD
Regorafenib—DDR2—uterine cervix—vulva cancer	0.0294	0.0294	CbGeAlD
Regorafenib—DDR2—mammalian vulva—vulva cancer	0.0257	0.0257	CbGeAlD
Regorafenib—DDR2—vagina—vulva cancer	0.0199	0.0199	CbGeAlD
Regorafenib—EPHX2—urethra—vulva cancer	0.0182	0.0182	CbGeAlD
Regorafenib—FLT4—epithelium—vulva cancer	0.0181	0.0181	CbGeAlD
Regorafenib—FGFR1—uterine cervix—vulva cancer	0.0177	0.0177	CbGeAlD
Regorafenib—EPHX2—mammalian vulva—vulva cancer	0.0174	0.0174	CbGeAlD
Regorafenib—FGFR1—urethra—vulva cancer	0.0162	0.0162	CbGeAlD
Regorafenib—RET—epithelium—vulva cancer	0.0159	0.0159	CbGeAlD
Regorafenib—FGFR1—mammalian vulva—vulva cancer	0.0155	0.0155	CbGeAlD
Regorafenib—FGFR2—epithelium—vulva cancer	0.0152	0.0152	CbGeAlD
Regorafenib—FGFR2—uterine cervix—vulva cancer	0.015	0.015	CbGeAlD
Regorafenib—EPHA2—epithelium—vulva cancer	0.0149	0.0149	CbGeAlD
Regorafenib—EPHA2—uterine cervix—vulva cancer	0.0148	0.0148	CbGeAlD
Regorafenib—TEK—epithelium—vulva cancer	0.0145	0.0145	CbGeAlD
Regorafenib—BRAF—vagina—vulva cancer	0.0141	0.0141	CbGeAlD
Regorafenib—FLT1—epithelium—vulva cancer	0.014	0.014	CbGeAlD
Regorafenib—RAF1—epithelium—vulva cancer	0.014	0.014	CbGeAlD
Regorafenib—FLT1—uterine cervix—vulva cancer	0.0139	0.0139	CbGeAlD
Regorafenib—RAF1—uterine cervix—vulva cancer	0.0138	0.0138	CbGeAlD
Regorafenib—EPHA2—urethra—vulva cancer	0.0136	0.0136	CbGeAlD
Regorafenib—EPHX2—vagina—vulva cancer	0.0135	0.0135	CbGeAlD
Regorafenib—TEK—urethra—vulva cancer	0.0132	0.0132	CbGeAlD
Regorafenib—EPHA2—mammalian vulva—vulva cancer	0.0129	0.0129	CbGeAlD
Regorafenib—DDR2—lymph node—vulva cancer	0.0129	0.0129	CbGeAlD
Regorafenib—FLT1—urethra—vulva cancer	0.0128	0.0128	CbGeAlD
Regorafenib—RAF1—urethra—vulva cancer	0.0127	0.0127	CbGeAlD
Regorafenib—MAPK11—lymph node—vulva cancer	0.0122	0.0122	CbGeAlD
Regorafenib—FLT1—mammalian vulva—vulva cancer	0.0122	0.0122	CbGeAlD
Regorafenib—RAF1—mammalian vulva—vulva cancer	0.0121	0.0121	CbGeAlD
Regorafenib—FGFR1—vagina—vulva cancer	0.012	0.012	CbGeAlD
Regorafenib—KDR—epithelium—vulva cancer	0.0119	0.0119	CbGeAlD
Regorafenib—KDR—uterine cervix—vulva cancer	0.0118	0.0118	CbGeAlD
Regorafenib—KDR—urethra—vulva cancer	0.0108	0.0108	CbGeAlD
Regorafenib—KIT—epithelium—vulva cancer	0.0105	0.0105	CbGeAlD
Regorafenib—KIT—uterine cervix—vulva cancer	0.0104	0.0104	CbGeAlD
Regorafenib—KDR—mammalian vulva—vulva cancer	0.0103	0.0103	CbGeAlD
Regorafenib—PDGFRB—epithelium—vulva cancer	0.0103	0.0103	CbGeAlD
Regorafenib—PDGFRB—uterine cervix—vulva cancer	0.0102	0.0102	CbGeAlD
Regorafenib—EPHA2—vagina—vulva cancer	0.01	0.01	CbGeAlD
Regorafenib—KIT—urethra—vulva cancer	0.00959	0.00959	CbGeAlD
Regorafenib—FLT1—vagina—vulva cancer	0.00944	0.00944	CbGeAlD
Regorafenib—RAF1—vagina—vulva cancer	0.00938	0.00938	CbGeAlD
Regorafenib—PDGFRB—urethra—vulva cancer	0.00936	0.00936	CbGeAlD
Regorafenib—KIT—mammalian vulva—vulva cancer	0.00913	0.00913	CbGeAlD
Regorafenib—BRAF—lymph node—vulva cancer	0.00911	0.00911	CbGeAlD
Regorafenib—ABL1—uterine cervix—vulva cancer	0.00908	0.00908	CbGeAlD
Regorafenib—PDGFRB—mammalian vulva—vulva cancer	0.00891	0.00891	CbGeAlD
Regorafenib—PDGFRA—vagina—vulva cancer	0.00884	0.00884	CbGeAlD
Regorafenib—EPHX2—lymph node—vulva cancer	0.0087	0.0087	CbGeAlD
Regorafenib—ABL1—urethra—vulva cancer	0.00834	0.00834	CbGeAlD
Regorafenib—KDR—vagina—vulva cancer	0.00798	0.00798	CbGeAlD
Regorafenib—ABL1—mammalian vulva—vulva cancer	0.00794	0.00794	CbGeAlD
Regorafenib—FLT4—lymph node—vulva cancer	0.00785	0.00785	CbGeAlD
Regorafenib—FGFR1—lymph node—vulva cancer	0.00774	0.00774	CbGeAlD
Regorafenib—KIT—vagina—vulva cancer	0.00707	0.00707	CbGeAlD
Regorafenib—RET—lymph node—vulva cancer	0.00693	0.00693	CbGeAlD
Regorafenib—PDGFRB—vagina—vulva cancer	0.0069	0.0069	CbGeAlD
Regorafenib—EPHA2—lymph node—vulva cancer	0.00647	0.00647	CbGeAlD
Regorafenib—TEK—lymph node—vulva cancer	0.00631	0.00631	CbGeAlD
Regorafenib—ABL1—vagina—vulva cancer	0.00615	0.00615	CbGeAlD
Regorafenib—FLT1—lymph node—vulva cancer	0.0061	0.0061	CbGeAlD
Regorafenib—RAF1—lymph node—vulva cancer	0.00607	0.00607	CbGeAlD
Regorafenib—ABCG2—uterine cervix—vulva cancer	0.00573	0.00573	CbGeAlD
Regorafenib—PDGFRA—lymph node—vulva cancer	0.00572	0.00572	CbGeAlD
Regorafenib—ABCG2—urethra—vulva cancer	0.00526	0.00526	CbGeAlD
Regorafenib—KDR—lymph node—vulva cancer	0.00516	0.00516	CbGeAlD
Regorafenib—ABCG2—mammalian vulva—vulva cancer	0.00501	0.00501	CbGeAlD
Regorafenib—CYP2C19—vagina—vulva cancer	0.00457	0.00457	CbGeAlD
Regorafenib—KIT—lymph node—vulva cancer	0.00457	0.00457	CbGeAlD
Regorafenib—PDGFRB—lymph node—vulva cancer	0.00447	0.00447	CbGeAlD
Regorafenib—CYP2C8—vagina—vulva cancer	0.00399	0.00399	CbGeAlD
Regorafenib—ABL1—lymph node—vulva cancer	0.00398	0.00398	CbGeAlD
Regorafenib—ABCG2—vagina—vulva cancer	0.00388	0.00388	CbGeAlD
Regorafenib—CYP2B6—vagina—vulva cancer	0.00358	0.00358	CbGeAlD
Regorafenib—ABCB1—epithelium—vulva cancer	0.00285	0.00285	CbGeAlD
Regorafenib—ABCB1—uterine cervix—vulva cancer	0.00282	0.00282	CbGeAlD
Regorafenib—ABCB1—urethra—vulva cancer	0.00259	0.00259	CbGeAlD
Regorafenib—ABCG2—lymph node—vulva cancer	0.00251	0.00251	CbGeAlD
Regorafenib—ABCB1—mammalian vulva—vulva cancer	0.00247	0.00247	CbGeAlD
Regorafenib—ABCB1—vagina—vulva cancer	0.00191	0.00191	CbGeAlD
Regorafenib—ABCB1—lymph node—vulva cancer	0.00124	0.00124	CbGeAlD
